| Literature DB >> 34916798 |
Alexandra Kasim1, Gabby Elbaz-Greener2,3, Amjad Shalabi4,5,6, Erez Kachel4,5,6, Liza Grosman-Rimon4,5, Michael Jerdev4, Offer Amir2,3,4,5, Shemy Carasso2,3,4,5.
Abstract
BACKGROUND: Severe mitral annulus calcification (MAC) is believed to bear high operative and post-operative risk during mitral valve replacement (MVR) surgery, including longer surgery time, post-surgical valvular leaks and increased rate of embolic phenomena. We hypothesized that quantification of mitral calcium in pre-operative chest computerized tomography (CCT), performed to assess aortic root before cross-clamping may help in risk assessment of adverse intraoperative and postoperative outcomes in patients undergoing MVR.Entities:
Keywords: MACS; MVR; mitral annulus calcification; mitral valve replacement
Mesh:
Substances:
Year: 2021 PMID: 34916798 PMCID: PMC8670886 DOI: 10.2147/VHRM.S338880
Source DB: PubMed Journal: Vasc Health Risk Manag ISSN: 1176-6344
Figure 1Mitral anatomy model. Viewed from the left atrium (Surgeon’s View). Anterior (A), Posterior (P) leaflet scallops numbered from 1–3, from lateral to medial.
Figure 2Slab image at the level of the mitral valve. Right images - virtual reality endoscopic reconstruction in 3D looking from the roof of the left atrium towards the mitral valve, showing calcium in in silver. Left images: Heart CT scan. (A) Patient without MAC, (B) Patient with MAC.
Figure 3Mitral annulus calcium scoring. (A) Low calcium score. (B) High Calcium Score.
Patient Characteristics by Mitral Calcium Score
| Total Cohort | Low MACS; Q1-Q3 n = 40 | High MACS; Q4-Q5 n = 26 | p-value | |
|---|---|---|---|---|
| Mitral Calcium score (Agatston units), median, (IQR) | 43 (0–862) | 0 (0–0) | 1024 (487–2394) | <0.001 |
| Agatston units, Range | 0−14,564 | 0–131 | 143–14,561 | |
| Mitral annulus calcification type | ||||
| Posterior, n, (%) | 20 (30) | 6 (15) | 14 (54) | |
| Anterior, n, (%) | 8 (12) | 1 (3) | 7 (27) | |
| Circumferential, n, (%) | 2 (3) | 0 (0) | 2 (8) | |
| Horseshoe, n, (%) | 4 (6) | 1 (3) | 3 (11) | |
| Age (years), median, (IQR) | 66 (58–70) | 65 (58–70) | 66 (40–71) | NS |
| Sex (male), n, (%) | 40 (64) | 29 (72) | 11 (42) | 0.02 |
| Diabetes Mellitus, n, (%) | 27 (44) | 13 (33) | 14 (54) | 0.09 |
| Hypertension, n, (%) | 48 (77) | 30 (75) | 18 (69) | NS |
| Hyperlipidemia, n, (%) | 36 (58) | 22 (55) | 14 (54) | NS |
| Chronic Renal Failure, n, (%) | 17 (27) | 11 (28) | 6 (23) | NS |
| Creatinine (mg/dl), median, IQR | 0.9 (0.7–1.1) | 0.9 (0.8–1.2) | 0.9 (0.6–1.1) | NS |
| COPD, n, (%) | 5 (8) | 4 (10) | 1 (4) | NS |
| CVA, n, (%) | 5 (8) | 5 (13) | 0 (0) | 0.06 |
| Rheumatic Heart Disease, n, (%) | 2 (3) | 2 (5) | 0 (0) | NS |
| Prior Myocardial Infarction, n, (%) | 16 (26) | 8 (20) | 8 (31) | NS |
| Previous Heart Surgery, n, (%) | 1 (2) | 0 (0) | 1 (4) | NS |
| Pre-Operative Echocardiography | ||||
| LVEDD, mm, median, (IQR) | 56 (52–61) | 56 (53–60) | 55 (49–62) | NS |
| LVESD, mm, median, (IQR) | 38 (34–44) | 38 (35–46) | 34 (33–41) | NS |
| LVEF, %, median, (IQR) | 50 (45–54) | 50 (45–55) | 49 (45–50) | NS |
| LASd, mm, median, (IQR) | 48 (44–55) | 47 (43–20) | 50 (47–57) | 0.002 |
| RVSP, mmHg, median, (IQR) | 41 (34–53) | 40 (34–48) | 44 (35–57) | NS |
| Indication for surgery | ||||
| MS, n, (%) | 22 (35) | 13(33) | 8 (31) | NS |
| MR, n, (%) | 36 (58) | 20(50) | 16 (62) | NS |
| MR+AS, n, (%) | 8 (13) | 6 (15) | 2 (8) | NS |
| Concomitant surgery, n, (%) | 49 (79) | 30 (75) | 19 (73) | NS |
Abbreviations: AS, aortic stenosis; COPD, chronic obstructive lung disease; CVA, cerebro vascular accident; IQR, interquartile range; LASd, left atrial systolic diameter; LVEF, left ventricle ejection fraction; LVESD, left ventricle end systolic diameter; MAC, mitral annulus calcification; MS, mitral stenosis; MR, mitral regurgitation; RVSP, right ventricular systolic pressure; TIA, transient ischemic attack.
Outcomes of Mitral Heart Surgery
| Total n = 66 | Low MACS; Q1-Q3 n = 40 | High MACS; Q4-Q5 n = 26 | p-value | |
|---|---|---|---|---|
| Mitral valve repair, n, (%) | 14 (21) | 11 (28) | 3 (12) | NS |
| Bypass time, min, median, (IQR) | 127 (113–147) | 128 (113–149) | 121 (113–143) | NS |
| Cross-clamp time, median, (IQR) | 96 (81–117) | 96 (84–116) | 95 (80–117) | NS |
| MAC intervention, n, (%) | ||||
| Decalcification | 47 (32( | 26 (65) | 21 (81) | NS |
| Annular plication | 14 (21) | 11 (28) | 3 (12) | NS |
| Pericardial patch | 0 (0) | 0 (0) | 0 (0) | NS |
| AV groove disruption | 0 (0) | 0 (0) | 0 (0) | NS |
| LVOT obstruction, n, (%) | 0 (0) | 0 (0) | 0 (0) | NS |
| Permanent pacing, n, (%) | 1 (2) | 1 (3) | 0 (0) | NS |
| Hospital stay, days, median, (IQR) | 9 (8–11) | 10 (8–11) | 9 (8–11) | NS |
| Creatinine, mg/dl, median, (IQR) | 0.9 (0.8–1.1) | 1.0 (0.9–1.2) | 0.8 (0.6–1) | 0.0025 |
| CVA, n, (%) | 5 (8) | 5 (13) | 0 (0) | NS |
| TIA, n, (%) | 0 (0) | 0 (0) | 0 (0) | NS |
| Other Embolism, mesenteric n, (%) | 1 (2) | 0 (0) | 1 (4) | NS |
| Hemodialysis, n, (%) | 6 (10) | 5 (13) | 1 (4) | NS |
| Re-thoracotomy, n, (%) | 1 (2) | 0 (0) | 1 (4) | NS |
| In-Hospital mortality, n, (%) | 1 (2) | 1 (2) | 0 (0) | NS |
| Post-operative Echocardiography | NS | |||
| MR PVL grade, median, (IQR) | 0 (0–1) | 0 (0–0) | 0 (0–1) | NS |
| Mitral mean gradient, median, (IQR) | 4 (3–6) | 4 (3–6) | 5 (2–6) | NS |
Abbreviations: CVA, cerebro vascular accident; IQR, interquartile range; MAC, mitral annulus calcification; TIA, transient ischemic attack.
Figure 4Post-operative embolic phenomena.